Table 2 Pathological features and stages of the patients
From: Clinical observation of the regeneration process of defects after breast cancer resection
Breast-conserving surgery group (n = 41) | Oxidized regenerated cellulose group (n = 41) | Gelatin sponge group (n = 43) | P | |
|---|---|---|---|---|
Pathological pattern (n) | 0.644 | |||
Invasive ductal carcinoma | 38 | 36 | 40 | |
Ductal carcinoma in situ | 3 | 5 | 3 | |
Tumor size (n) | 0.916 | |||
Tis | 3 | 5 | 3 | |
T1 | 29 | 28 | 30 | |
T2 | 9 | 8 | 10 | |
Lymph node status (n) | 0.866 | |||
N0 | 35 | 36 | 36 | |
N1 | 6 | 5 | 7 | |
Staging (n) | ||||
0 | 3 | 5 | 3 | 0.883 |
1A | 26 | 25 | 28 | |
2A | 8 | 9 | 7 | |
2B | 4 | 2 | 5 | |
ER status (n) | 0.533 | |||
Positive | 26 | 30 | 27 | |
Negative | 15 | 11 | 16 | |
PR status (n) | 0.736 | |||
Positive | 25 | 22 | 23 | |
Negative | 16 | 19 | 20 | |
HER-2 status (n) | 0.752 | |||
Positive | 8 | 5 | 10 | |
Negative | 33 | 36 | 33 | |
Triple negative breast cancer (n) | 8 | 7 | 9 | |
Adjuvant chemotherapy (n) | 0.877 | |||
Yes | 30 | 28 | 31 | |
No | 11 | 13 | 12 | |
Endocrine therapy (n) | ||||
Yes | 29 | 34 | 32 | 0.415 |
No | 12 | 7 | 11 |